Glucagon-like peptide 1 receptor messenger RNA 3' untranslated region (GLP1R mRNA 3' UTR)

The Glucagon-like peptide 1 receptor (GLP1R) mRNA 3' untranslated region (3' UTR) is a critical non-coding segment of the GLP1R transcript that governs the post-transcriptional fate of the messenger RNA. This region contains specific sequences recognized by microRNAs (miRNAs) and RNA-binding proteins, which together modulate the stability and translation efficiency of the mRNA. In patients with type 2 diabetes, the expression of GLP1R is often significantly reduced in pancreatic beta cells, a phenomenon linked to the upregulation of specific miRNAs like miR-204 that bind to the 3' UTR and trigger mRNA degradation or translational repression (Jo et al., 2018, Nature Communications). Consequently, the GLP1R mRNA 3' UTR has emerged as a strategic target for RNA-based therapeutics designed to restore receptor levels and enhance insulinotropic capacity. Experimental drugs, such as antisense oligonucleotides (ASOs) and miRNA inhibitors, are being developed to block these inhibitory interactions, thereby increasing the density of GLP1R on the cell surface (Shrestha et al., 2015, Scientific Reports). This approach offers a potential advantage over traditional GLP-1 analogues by addressing the root cause of reduced receptor availability rather than merely stimulating the remaining receptors. Successful modulation of this target could lead to improved glucose-stimulated insulin secretion and better long-term management of metabolic disorders (Taneera et al., 2012, Cell Metabolism).

Other names

GLP-1R 3' UTRGLP1R 3-prime untranslated regionGlucagon-like peptide 1 receptor 3' untranslated region

The target acts as a regulatory hub where antisense oligonucleotides or microRNA inhibitors bind to prevent the recruitment of the RNA-induced silencing complex (RISC), thereby protecting the GLP1R mRNA from degradation or translational inhibition and increasing the production of the GLP1R protein.